Focused On-demand Library for D(3) dopamine receptor

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P35462

UPID:
DRD3_HUMAN

ALTERNATIVE NAMES:
Dopamine D3 receptor

ALTERNATIVE UPACC:
P35462; A1A4V5; Q4VBM8

BACKGROUND:
Dopamine D3 receptor, encoded by the gene with accession number P35462, is integral to dopamine-mediated neurotransmission. It inhibits adenylyl cyclase via G protein signaling, influencing both brain activity and cell proliferation.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of the D(3) dopamine receptor could open doors to potential therapeutic strategies. Its association with diseases like hereditary essential tremor and schizophrenia underscores its significance in neurodegenerative and psychiatric disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.